Lexaria's Human Study GLP-1-H26-7 Reaches Full Enrollment and Continues Dosing on Schedule
ACCESSWIRE•21/10/2026•09:25 ET
4
Key Highlights
- ➤GLP-1-H26-7 reaches full enrollment; final arm began dosing in early October
- ➤Final group expected to complete dosing in mid-November
- ➤Study compares two DHT-semaglutide compositions against Wegovy tablets
- ➤Five-week study evaluates safety, tolerability, and pharmacokinetic properties
- ➤Lexaria’s tablet and capsule formulations include SNAC for the first multi-week human evaluation
KELOWNA, BC / ACCESS Newswire / October 21, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, reports that full enrollment has been reached and dosing continues on schedule with Human Pilot Study #7 (GLP-1-H26-7) which is evaluating two oral DehydraTECH-semaglutide ("DHT-sema") compositions against Novo's® commercially available Wegovy® tablets, over a 5-week duration (the "Study").
The final Study arm was fully enrolled and began dosing, as scheduled, in early October. This final group is expected to complete their dosing in mid-November, to be followed by completion of all laboratory sample analyses and reporting.
Get started
Create a free account to read the full story.